NAD+ Patches vs Oral Supplements: What the Evidence Shows

First, what does “NAD+ supplement” mean?

Nicotinamide adenine dinucleotide, usually written as NAD+, is a coenzyme involved in cellular metabolism. It is not the same ingredient as nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR). NMN and NR are precursors that participate in pathways the body uses to make NAD+. This distinction matters when comparing labels: a capsule containing NMN, a capsule containing NR, a product listing NAD+ itself, and a patch listing one of these ingredients are not interchangeable products.

The phrase “oral NAD+ supplement” is also used loosely in marketing. Many of the better-known human supplementation trials studied oral NMN or NR, not a conventional capsule of intact NAD+ and not a transdermal patch. A study on one precursor or delivery form cannot establish the absorption or effect of a different ingredient. When reading a product page, start with the Supplement Facts or ingredient panel and identify the exact compound, amount, and route.

For a patch, check whether the label lists NAD+, NMN, NR, or a blend. Then ask what “amount” means. It could describe the material loaded into the patch, the amount applied to the skin, or an amount the manufacturer estimates will be delivered. Those are not necessarily the same. The product-specific human evidence should explain what was measured and how the delivered dose was determined.

Can an NAD+ patch deliver its ingredients through the skin?

A transdermal patch is a delivery system, not proof of absorption. Its performance depends on the active ingredient, the formulation, the patch design, how long it is worn, and whether it uses a technology such as iontophoresis or microneedles. Evidence that one approved medicine can be delivered through skin does not show that every vitamin, coenzyme, or supplement ingredient will cross the skin at a useful dose.

This is why phrases such as “bypasses digestion,” “steady release,” or “better absorption” need product-specific evidence. A patch could be easier to use for someone who dislikes capsules, yet convenience does not establish that the active ingredient reaches the bloodstream. To support an absorption claim, look for a human pharmacokinetic study of the exact patch formula, with a clear measure of NAD+ or related metabolites and enough information to understand the study design.

The published human patch example located for this article was not a typical passive adhesive wellness patch. It used an iontophoresis device to apply NAD+ in a small observational pilot for persistent fatigue after COVID-19. Participants also received low-dose naltrexone, and the study did not include a control group. The design can describe what happened during that combined treatment, but it cannot tell whether the patch alone caused the reported changes or whether a retail patch delivers a comparable amount. [1]

What have human studies found about NAD+ patches?

In the 2024 pilot, 36 people with persistent fatigue after COVID-19 received a combination of low-dose naltrexone and NAD+ delivered by iontophoresis patches. Thirty-one participants were included in the efficacy analysis. Average fatigue and quality-of-life questionnaire scores improved from baseline over 12 weeks, and some participants reported temporary irritation where the patch was applied. However, the study was open-label and single-arm: there was no placebo or comparison group. It also combined the patch with naltrexone, so the contribution of each treatment cannot be separated. [1]

That pilot is useful because it shows that researchers have explored a device-assisted NAD+ route in humans. It is not evidence that a standard over-the-counter patch raises blood NAD+, prevents age-related decline, improves energy in healthy adults, or outperforms oral NMN or NR. The population, treatment combination, device, and outcomes all differ from the claims commonly made for consumer patches.

If a brand cites a patch study, compare the product with the tested intervention point by point: ingredient, amount, delivery technology, wear time, participant group, control group, and outcome. “The study used a patch” is not enough if the tested patch was powered, compounded, used alongside a prescription treatment, or aimed at a different condition.

What have oral NMN and NR studies found?

Oral precursors have a more developed human research record than consumer NAD+ patches, although it remains limited. In one randomized, placebo-controlled study, 30 healthy adults received 250 mg of NMN per day or placebo for 12 weeks. Whole-blood NAD+ measurements increased in the NMN group. The trial was small and short, and changes in a blood biomarker do not establish a lasting improvement in health, aging, or daily function. [2]

A separate eight-week randomized trial in 140 overweight but otherwise healthy adults tested oral NR at 100, 300, or 1,000 mg per day. Whole-blood NAD+ rose in a dose-related pattern in the study, while the investigators monitored safety and related metabolites. This supports an effect on measured blood NAD+ for the tested NR product and duration. It does not demonstrate that NR improves every health outcome or that an NAD+ patch would produce the same effect. The study also disclosed industry relationships and funding, which readers can consider alongside its design and findings. [3]

A 2026 randomized, open-label study in 65 healthy participants compared oral nicotinamide, NR, and NMN over 14 days. NR and NMN increased circulating NAD+ measures, while nicotinamide did not show the same result during that short study. It compared oral ingredients with one another, not oral supplements with a patch, and it did not establish a long-term health benefit. [4]

Together, these trials support a narrow conclusion: some oral precursors can change blood NAD-related measurements under studied conditions. They do not prove that a person will feel a noticeable difference, that a higher dose is better, or that changing the delivery route improves results. Blood levels are one research endpoint, not a substitute for outcomes that matter to a person.

Are NAD+ patches better for absorption or steadier levels?

There is not enough direct human evidence to answer yes. To show that a patch offers better absorption, a study would need to compare the patch with a clearly defined oral product, measure the same NAD-related outcomes over appropriate time points, and report how much active ingredient reached circulation. A claim about “steady levels” would also require repeated measurements over time, not a statement about how a patch is designed to release its contents.

The same standard applies to digestion claims. A patch avoids swallowing a capsule, but that does not prove fewer side effects overall or better tolerance for every user. One small patch pilot reported local skin irritation, while oral studies measured tolerability for particular NMN or NR products. These are not comparable safety tests because they involved different populations, formulas, and designs.

For now, “better” depends on what matters to you. If you prioritize published human biomarker studies, oral NMN and NR have more directly relevant evidence than consumer patches. If you prioritize avoiding pills, a patch may be more convenient, but treat absorption and outcome claims as unproven unless the brand provides product-specific human data. Neither route should be chosen on the assumption that raising a blood marker automatically slows aging.

How can you evaluate a patch or oral product?

1. Identify the active ingredient. Confirm whether it is NAD+, NMN, NR, or a blend. Do not treat the names as synonyms.
2. Understand the dose statement. For a patch, ask whether the amount is loaded, applied, or shown to be delivered. For an oral product, confirm the amount per full serving and how many capsules make that serving.
3. Look for product-specific human data. Check whether the exact ingredient and delivery system were studied in people, whether there was a control group, how many participants completed the trial, and what the researchers measured.
4. Separate the endpoint from the promise. A change in blood NAD+ is a biomarker result. It does not, by itself, show better energy, sleep, skin, cognition, or lifespan.
5. Review quality and other ingredients. Check the manufacturer, ingredient identity and potency testing, the complete formula, patch adhesive materials, and any batch-level quality documentation. Quality checks help establish what is in a product; they do not prove effectiveness.
6. Compare practical fit and cost. Consider ease of use, skin sensitivity, swallowing preference, serving frequency, and cost per labeled serving. A higher price or a newer delivery format is not evidence of better results.

Be cautious with “FDA approved” wording. In the United States, FDA does not approve dietary supplements for safety and effectiveness before they are marketed. A facility registration or a reference to manufacturing standards is not the same as FDA approval of a specific product's claimed benefit. [5]

Safety and realistic expectations

The available oral trials were limited in duration and studied specific formulations; they cannot settle long-term safety for every person or product. Patches add the possibility of local irritation from the active ingredient, adhesive, or delivery method. Follow the product directions and stop using it if the skin becomes painful or develops a persistent rash.

Talk with a qualified healthcare professional before starting a supplement if you take medication, have a medical condition, are pregnant or nursing, or are considering a patch-based treatment for ongoing symptoms. Do not use an NAD+ product to diagnose, treat, or prevent a condition or to replace prescribed care. A research result from a long-COVID pilot should not be taken as a recommendation to self-treat long COVID.

Frequently asked questions

Do NAD+ patches work?

A small observational study explored NAD+ delivered by an iontophoresis device together with low-dose naltrexone in people with persistent post-COVID fatigue. It does not establish whether a typical consumer patch delivers NAD+ or improves health outcomes on its own.

Are patches better absorbed than oral NMN or NR?

The human studies cited here do not directly compare a standard patch with oral NMN or NR. A manufacturer would need product-specific human absorption data to support that claim.

Is NMN the same as NAD+?

No. NAD+ is a coenzyme, while NMN and NR are different compounds used as precursors in NAD-related pathways. Check the exact ingredient on the label.

Do patches avoid digestive side effects?

A patch avoids swallowing a product, but there is not enough head-to-head evidence to claim that patches cause fewer overall side effects. Local skin irritation has been reported in a small iontophoresis-patch pilot.

Can an NAD+ patch replace an oral supplement?

There is no established dose conversion between patches and oral NMN or NR. Compare the specific formula and evidence rather than assuming that one patch equals a capsule or serving.

For a fair comparison, look beyond the route printed on the package. Oral NMN and NR have human evidence for changes in blood NAD-related markers, while published patch evidence is limited to a small, device-assisted combination pilot in a specific patient group. Until direct product-specific comparisons are available, convenience can guide personal preference, but claims of superior absorption or results should remain unproven.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.